Recurrent Melanoma Completed Phase 1 Trials for DB00398 (Sorafenib)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00349206Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaTreatment